Skip to main content
Vericel Corp logo

Vericel Corp — Investor Relations & Filings

Ticker · VCEL ISIN · US92346J1088 LEI · 54930076YM3PLTDR4B91 US Manufacturing
Open in API
Filings indexed 1,130 across all filing types
Latest filing 2012-03-23 Regulatory Filings
Country US United States of America
Listing US VCEL

About Vericel Corp

https://vcel.com/

Vericel Corporation is a biopharmaceutical company that develops, manufactures, and commercializes advanced cell therapies for the sports medicine and severe burn care markets. The company's portfolio is centered on autologous (patient-specific) cell-based products. Key commercial products include MACI® (autologous cultured chondrocytes on porcine collagen membrane), a tissue-engineered product for the repair of symptomatic cartilage defects of the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for patients with severe burns. Additionally, Vericel holds the exclusive North American commercial rights for NexoBrid®, a biological orphan product used for the removal of eschar in adults with deep partial-thickness or full-thickness thermal burns.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2012
Regulatory Filings
2012-03-23 English
DEL AM
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC referencing a Registration Statement on Form S-3 filed by Aastrom Biosciences. It is described as a delaying amendment pursuant to Rule 473 of the Securities Act of 1933, which is a procedural filing to delay the effective date of the registration statement. The document is short (1836 characters) and does not contain financial data or report content. It is an amendment related to a registration statement, which is a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as it is a procedural SEC filing and not a financial report or announcement of a report.
2012-03-22 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes details about the securities being registered, offering price, and legal disclaimers. The text references the Securities Act of 1933 and Rule 415, indicating it is related to capital raising activities. There is no financial performance data, earnings information, or management discussion typical of annual or quarterly reports. The document is not an announcement of a report but a registration statement for securities issuance. Therefore, it fits the category of Capital/Financing Update filings.
2012-03-19 English
10-K
Annual Report FY 2011
2012-03-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2012, by Aastrom Biosciences, Inc. It details the entry into a material definitive agreement involving the sale of Series B-1 Non-Voting Preferred Stock and Series B-2 Voting Preferred Stock, including terms of conversion, dividends, redemption rights, and voting rights. The content focuses on a financing transaction and capital structure changes, specifically a private placement of preferred stock and related agreements. There is no indication that this is an earnings release, annual report, or other report type. The detailed description of the securities issuance and terms aligns with a Capital/Financing Update. The document is substantive and not merely an announcement or certification, so it is not Regulatory Filings or Report Publication Announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2012-03-09 English
FORM 8-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. It references a press release attached as Exhibit 99.1 dated March 9, 2012. The document is short (2568 characters) and primarily serves as a notification of an event rather than containing detailed financial data or comprehensive reports. It does not contain financial statements or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-03-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.